{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T19:50:28Z","timestamp":1793821828662,"version":"4.6.1"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The prognostic significance of platelet-to-lymphocyte ratio (PLR) in non-muscle invasive bladder cancer (NMIBC) remains controversial despite numerous investigations. This study aimed to systematically evaluate the prognostic value of PLR in NMIBC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>An extensive systematic search was executed utilizing four major electronic databases: Embase, PubMed, Web of Science, and Cochrane Library. The prognostic significance of PLR was assessed using pooled hazard ratios (HRs) with 95% CIs. Forest plots were used to present data visualization and statistical summaries, illustrating the effects of individual studies and the reliability of the pooled results. Funnel plot analysis and Egger\u2019s test were employed to evaluate the potential presence of publication bias. Sensitivity analysis was performed to assess the robustness of the pooled findings. Subgroup analysis and meta-regression were used to identify sources of heterogeneity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eleven retrospective studies encomprising 3,566 patients met the inclusion criteria. Elevated PLR notably correlated with inferior progression-free survival (PFS) (HR=2.132, 95% CI: 1.146-3.967, p=0.017) and relapse-free survival (RFS) (HR=1.732, 95% CI: 1.174-2.554, p=0.006). No statistically meaningful correlation emerged in cancer-specific survival (CSS) (HR=1.218, 95% CI: 0.800-1.854, p=0.358) or overall survival (OS) (HR=1.350, 95% CI: 0.611-2.983, p=0.459). Publication bias was detected in RFS analyses (Egger\u2019s test, P=0.010). Sensitivity analysis demonstrated that the pooled results were robust. Subgroup analysis and meta-regression identified geographic differences and patient characteristics as key sources of heterogeneity in RFS outcomes. Subgroup analysis indicated that geographic differences and sample size were potential sources of heterogeneity in PFS results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This study comprehensively analyzed 11 studies and 3,566 NMIBC cases and found that elevated PLR was significantly associated with poorer RFS and PFS, suggesting that PLR can be used as a prognostic biomarker for the management of NMIBC. The prognostic value of PLR may be related to immune regulation and inflammatory response in the tumor microenvironment; nevertheless, further studies are needed to elucidate its mechanism and establish its clinical application.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study demonstrates that elevated PLR serves as an independent predictor of poor PFS and RFS in NMIBC patients. As a cost-effective biomarker, PLR shows promise in risk stratification and treatment planning. However, large-scale prospective studies are warranted to validate these findings and establish standardized cut-off values.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD42024621307<\/jats:ext-link>\n                      <jats:bold>, identifier CRD42024621307.<\/jats:bold>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1578069","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T01:30:54Z","timestamp":1747099854000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Elevated platelet-to-lymphocyte ratio predicts poor clinical outcomes in non-muscle invasive bladder cancer: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Wenfeng","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinze","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaichun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinwen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e076743","DOI":"10.1136\/bmj-2023-076743","article-title":"Advances in diagnosis and treatment of bladder cancer","volume":"384","author":"Lopez-Beltran","year":"2024","journal-title":"BMJ"},{"key":"B3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European association of urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2023.1327053","article-title":"BCG induced lower urinary tract symptoms during treatment for NMIBC-Mechanisms and management strategies","volume":"17","author":"Bourlotos","year":"2023","journal-title":"Front Neurosci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.17598","article-title":"Bladder cancer: A review","volume":"324","author":"Lenis","year":"2020","journal-title":"Jama"},{"key":"B6","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.eururo.2011.05.045","article-title":"Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review","volume":"60","author":"van den Bosch","year":"2011","journal-title":"Eur Urol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21631","article-title":"Treatment of muscle-invasive and advanced bladder cancer in 2020","volume":"70","author":"Patel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-021-00481-1","article-title":"100 years of Bacillus Calmette-Gu\u00e9rin immunotherapy: from cattle to COVID-19","volume":"18","author":"Lobo","year":"2021","journal-title":"Nat Rev Urol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajur.2021.05.002","article-title":"Intravesical bacillus Calmette-Guerin (BCG) in treating non-muscle invasive bladder cancer-analysis of adverse effects and effectiveness of two strains of BCG (Danish 1331 and Moscow-I)","volume":"9","author":"Thyavihally","year":"2022","journal-title":"Asian J Urol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.7086","article-title":"Outcomes of a dietary intervention to reduce bladder cancer recurrence and progression in survivors of non-muscle-invasive bladder cancer","volume":"22","author":"Yeary","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/medicina56010015","article-title":"Tumor microenvironment","volume":"56","author":"Arneth","year":"2019","journal-title":"Med (Kaunas)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.2015.1059279","article-title":"The importance of the tumor microenvironment in the therapeutic management of cancer","volume":"15","author":"Pottier","year":"2015","journal-title":"Expert Rev Anticancer Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2012.211","article-title":"The relationships between cellular components of the peritumoural inflammatory response, clinicopathological characteristics and survival in patients with primary operable colorectal cancer","volume":"106","author":"Richards","year":"2012","journal-title":"Br J Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cca.2018.04.023","article-title":"Platelet-to-lymphocyte ratio in advanced Cancer: Review and meta-analysis","volume":"483","author":"Li","year":"2018","journal-title":"Clin Chim Acta"},{"key":"B16","doi-asserted-by":"publisher","first-page":"7375169","DOI":"10.1155\/2018\/7375169","article-title":"Prognostic significance of platelet-to-lymphocyte ratio in cholangiocarcinoma: A meta-analysis","volume":"2018","author":"Hu","year":"2018","journal-title":"BioMed Res Int"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/DCR.0000000000002291","article-title":"Prognostic significance of lymphocyte-to-monocyte and platelet-to-lymphocyte ratio in rectal cancer: A systematic review, meta-analysis, and meta-regression","volume":"65","author":"Hamid","year":"2022","journal-title":"Dis Colon Rectum"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00757","article-title":"Prognostic role of platelet-to-lymphocyte ratio in patients with bladder cancer: A meta-analysis","volume":"9","author":"Wang","year":"2019","journal-title":"Front Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.15281","article-title":"Prognostic role of platelet to lymphocyte ratio in hepatocellular carcinoma: a systematic review and meta-analysis","volume":"8","author":"Zhao","year":"2017","journal-title":"Oncotarget"},{"key":"B20","doi-asserted-by":"publisher","first-page":"9503025","DOI":"10.1155\/2017\/9503025","article-title":"High platelet-to-lymphocyte ratio predicts poor prognosis and clinicopathological characteristics in patients with breast cancer: A meta-analysis","volume":"2017","author":"Zhang","year":"2017","journal-title":"BioMed Res Int"},{"key":"B21","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2217\/bmm-2016-0181","article-title":"The prognostic role of pretreatment platelet-to-lymphocyte ratio as predictors in patients with colorectal cancer: a meta-analysis","volume":"11","author":"Min","year":"2017","journal-title":"biomark Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e12504","DOI":"10.1097\/MD.0000000000012504","article-title":"Prognostic role of platelet to lymphocyte ratio in prostate cancer: A meta-analysis","volume":"97","author":"Wang","year":"2018","journal-title":"Med (Baltimore)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.v139.1","article-title":"Prognostic role of platelet to lymphocyte ratio in non-small cell lung cancers: A meta-analysis including 3,720 patients","volume":"139","author":"Zhao","year":"2016","journal-title":"Int J Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.4103\/njcp.njcp_399_22","article-title":"Can peripheral blood systemic immune response parameters predict oncological outcomes in patients with non-muscle-invasive bladder cancer","volume":"26","author":"Caglayan","year":"2023","journal-title":"Niger J Clin Pract"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S393511","article-title":"Preoperative systemic inflammatory markers as a significant prognostic factor after TURBT in patients with non-muscle-invasive bladder cancer","volume":"16","author":"Ding","year":"2023","journal-title":"J Inflammation Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/bju.16486","article-title":"Prognostic role of the neutrophil\/lymphocyte ratio in high-risk BCG-na\u00efve non-muscle-invasive bladder cancer treated with intravesical gemcitabine\/docetaxel","volume":"135","author":"Chakra","year":"2025","journal-title":"BJU Int"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.14179","article-title":"Preoperative neutrophil-lymphocyte ratio can significantly predict mortality outcomes in patients with non-muscle invasive bladder cancer undergoing transurethral resection of bladder tumor","volume":"8","author":"Kang","year":"2017","journal-title":"Oncotarget"},{"key":"B30","article-title":"Prognostic value of preoperative systemic inflammatory responses in patients with non-muscle invasive bladder cancer undergoing transurethral resection of bladder tumor","volume":"5","author":"Shi-Yu Mao","year":"2017","journal-title":"Int J Clin Exp Pathol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1101830","article-title":"The different predictive value of mean platelet volume-to-lymphocyte ratio for postoperative recurrence between non-muscular invasive bladder cancer patients treated with intravesical chemotherapy and intravesical chemohyperthermia","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1177\/03936155241261719","article-title":"The prognostic significance of preoperative platelet-to-lymphocyte ratio and interleukin-6 level in non-muscle invasive bladder cancer","volume":"39","author":"Wang","year":"2024","journal-title":"Int J Biol Markers"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fsurg.2022.907485","article-title":"Prognostic value of platelet-to-lymphocyte ratio in non-muscle invasive bladder cancer patients: intravesical bacillus calmette-guerin treatment after transurethral resection of bladder tumor","volume":"9","author":"Wu","year":"2022","journal-title":"Front Surg"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1189086","article-title":"The relationship between inflammatory response markers and the prognosis of non-muscle invasive bladder cancer and the development of a nomogram model","volume":"13","author":"Yi","year":"2023","journal-title":"Front Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00642","article-title":"Elevated neutrophil to lymphocyte ratio predicts poor prognosis in non-muscle invasive bladder cancer patients: initial intravesical bacillus calmette-guerin treatment after transurethral resection of bladder tumor setting","volume":"8","author":"Yuk","year":"2018","journal-title":"Front Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.4274\/uob.galenos.2023.2023.2.1","article-title":"Prognostic values of inflammatory markers in patients with high-grade lamina propria-invasive bladder cancer","volume":"23","author":"Yilmaz","year":"2024","journal-title":"Bull Urooncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e101119","DOI":"10.1371\/journal.pone.0101119","article-title":"Prognostic value of PLR in various cancers: a meta-analysis","volume":"9","author":"Zhou","year":"2014","journal-title":"PloS One"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-14-0146","article-title":"Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis","volume":"23","author":"Templeton","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1177403","article-title":"The preoperative platelet to neutrophil ratio and lymphocyte to monocyte ratio are superior prognostic indicators compared with other inflammatory biomarkers in ovarian cancer","volume":"14","author":"Song","year":"2023","journal-title":"Front Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2017.09.006","article-title":"Platelet to lymphocyte ratio in biliary tract cancer: Review and meta-analysis","volume":"474","author":"Zhou","year":"2017","journal-title":"Clin Chim Acta"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1408700","article-title":"Prognostic value of inflammatory markers NLR, PLR, and LMR in gastric cancer patients treated with immune checkpoint inhibitors: a meta-analysis and systematic review","volume":"15","author":"Tan","year":"2024","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"106677","DOI":"10.1016\/j.intimp.2020.106677","article-title":"Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis","volume":"85","author":"Zhang","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/nature07205","article-title":"Cancer-related inflammation","volume":"454","author":"Mantovani","year":"2008","journal-title":"Nature"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.01.025","article-title":"Immunity, inflammation, and cancer","volume":"140","author":"Grivennikov","year":"2010","journal-title":"Cell"},{"key":"B46","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.ejim.2013.01.017","article-title":"The platelet-cancer loop","volume":"24","author":"Goubran","year":"2013","journal-title":"Eur J Intern Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2014.04.006","article-title":"Platelets effects on tumor growth","volume":"41","author":"Goubran","year":"2014","journal-title":"Semin Oncol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1055\/s-0034-1370767","article-title":"Platelet-cancer interactions","volume":"40","author":"Goubran","year":"2014","journal-title":"Semin Thromb Hemost"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.v113:5","article-title":"Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer","volume":"113","author":"Janowska-Wieczorek","year":"2005","journal-title":"Int J Cancer"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2013.05.008","article-title":"Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor","volume":"24","author":"Schumacher","year":"2013","journal-title":"Cancer Cell"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1108121108","article-title":"Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model","volume":"108","author":"Meyer","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-2123","article-title":"Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity","volume":"69","author":"Kopp","year":"2009","journal-title":"Cancer Res"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-06-2272","article-title":"Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells","volume":"105","author":"Palumbo","year":"2005","journal-title":"Blood"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-00565-9","article-title":"Tumor-infiltrating lymphocytes in the immunotherapy era","volume":"18","author":"Paijens","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-011-0006-x","article-title":"Intratumoral regulatory T cells alone or in combination with cytotoxic T cells predict prognosis of hepatocellular carcinoma after resection","volume":"29","author":"Chen","year":"2012","journal-title":"Med Oncol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/bjc.2011.189","article-title":"The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis","volume":"105","author":"Gooden","year":"2011","journal-title":"Br J Cancer"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3611","article-title":"Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms","volume":"13","author":"Elinav","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.5037","article-title":"Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer","volume":"29","author":"Mahmoud","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1578069\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T01:30:55Z","timestamp":1747099855000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1578069\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,13]]},"references-count":58,"alternative-id":["10.3389\/fimmu.2025.1578069"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1578069","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,13]]},"article-number":"1578069"}}